Chargement des cours...
Prévisions
L'objectif de cours moyen des analystes est de 440,62 € (+11,03 %). La médiane est de 454,36 € (+14,49 %).
| Acheter |
40 |
| Conserver |
12 |
| Vendre |
5 |
Discussions dans la communauté
Il n'y a pas encore de discussion sur cet actif.
Lancer une discussionActualités Accéder au fil d'actualités
Intuitive Surgical impresses with quarterly results and offers further upside potential
Intuitive Surgical reported third-quarter revenue growth of 22% and an increase in procedures of about 15%. Analysts see tailwinds from the new da Vinci 5 and sustained demand in parts of Europe; Baird raised its price target to $550. The stock shows relative strength, is poised to break above $458, and market experts attribute roughly 25% more upside to the shares. » Plus sur deraktionaer.de
Intuitive Surgical back at yearly high after Q3 numbers – stock rebounds after sell-off
Intuitive Surgical beat revenue and earnings expectations in the third quarter, pushing the share price back up after a temporary pullback of around ten percent. The stock outperformed the market and briefly reached its highest level since May, sustainably breaking above the 200-day moving average. Analysts view the pullback as a buying opportunity despite concerns about comparison effects and growth worries in the U.S. » Plus sur deraktionaer.de
Intuitive Surgical beats expectations, stock falls after $450m settlement
Intuitive Surgical reported third-quarter revenue up 22% to $3.05 billion and adjusted earnings per share of $3.00, both well above analysts’ estimates. Procedures using surgical robots rose 15% and the installed base of Da‑Vinci systems topped 12,000 units for the first time. Despite the strong results, the stock sank by just over ten percent at one point after the company said it will pay a $450 million settlement. Intuitive holds $6.8 billion in cash and announced share buybacks of about $2.94 billion. » Plus sur deraktionaer.de
Intuitive Surgical ahead of quarterly results: US procedures and guidance in focus
Intuitive Surgical will report third-quarter results on Tuesday after the US market close. Analysts expect revenue of $2.91 billion and adjusted earnings per share of $2.65. Key for the stock is whether management classifies the slowed growth in Da Vinci procedures in the US as temporary and raises the full-year guidance; the shares are currently about 30% below their 52-week high and just under the 200-day moving average. Competitive pressure from Stryker and CMR Surgical is cited as an additional risk factor. » Plus sur deraktionaer.de
Intuitive Surgical: growth slows, outlook remains confirmed
At the Wells‑Fargo conference, Intuitive Surgical reported a slowdown in growth of U.S. procedure volumes but reaffirmed its guidance for global procedure growth of 13.5–15.5% and expects results near the midpoint. The company reported robust revenue, margin and free‑cash‑flow growth in the first half and highlighted support from system upgrades, the launch of the da Vinci 5, expansion into ambulatory surgery centers, and AI and software offerings. Competitive pressure from new market entrants and challenges in China, as well as a decline in bariatric procedures, are cited as headwinds; the operating margin target remains 35–40% and significant share buybacks have been carried out. » Plus sur de.investing.com
Données financières de l'entreprise
| (EUR) | septembre 2026 | YoY |
|---|---|---|
| Chiffre d'affaires | 2,69 Md | 26,09 % |
| Bénéfice brut | 1,84 Md | 29,90 % |
| Bénéfice net | 461,55 M | 23,11 % |
| EBITDA | 590,1 M | 31,79 % |
Données fondamentales
| Indicateur | Valeur |
|---|---|
Capitalisation boursière | 139,73 Md € |
Nombre d'actions | 346,64 M |
Plus haut/bas sur 52 semaines | 548,76 € - 298,58 € |
| Dividendes | Non |
Bêta | 1,44 |
Ratio P/E | 53,00 |
Ratio PEG | 5,99 |
Ratio P/B | 9,68 |
Ratio P/S | 13,28 |
Profil de l'entreprise
Intuitive Surgical, Inc. développe, fabrique et commercialise des produits permettant aux médecins et aux prestataires de soins de santé d'améliorer la qualité des soins mini-invasifs et l'accès à ceux-ci, aux États-Unis et à l'international. La société propose le système chirurgical da Vinci, qui permet de réaliser des interventions chirurgicales complexes selon une approche mini-invasive ; ainsi que le système endoluminal Ion, qui élargit son offre commerciale au-delà de la chirurgie vers les procédures de diagnostic, en permettant des biopsies mini-invasives du poumon. Elle fournit également une gamme d'instruments d'agrafage, d'énergie et d'instrumentation de base pour ses systèmes chirurgicaux ; des parcours de formation progressifs destinés à accompagner l'utilisation de sa technologie ; un ensemble de services à ses clients, notamment l'assistance, l'installation, la réparation et la maintenance ; ainsi que des fonctionnalités numériques intégrées offrant des solutions unifiées et connectées, et rationalisant les performances des hôpitaux grâce à des analyses améliorant les programmes. La société a été constituée en 1995 et son siège social se situe à Sunnyvale, en Californie.
| Nom | Intuitive Surgical |
| PDG | David J. Rosa |
| Siège social | Sunnyvale,
ca États-Unis |
| Site web | |
| Secteur | Santé |
| Industrie | Technologies de la santé |
| Introduction en bourse | 10/08/2023 |
| Employés | 17 021 |
Symboles boursiers
| Bourse | Symbole |
|---|---|
NASDAQ | ISRG |
London Stock Exchange | 0R29.L |
XETRA | IUI1.DE |
Frankfurt | IUI1.F |
Düsseldorf | IUI1.DU |
Hamburg | IUI1.HM |
Milan | 1ISRG.MI |
London | 0R29.L |
SIX | ISRG.SW |
München | IUI1.MU |
Wien | ISRG.VI |